Over 2 million long bone fractures are treated in the United States every year. Although most bone fractures heal spontaneously there is no gold standard for promoting bone regeneration in those settings in which either fractures do not heal or there is a critical sized segmental bone defect due to trauma or infection, devastating medical problems leading to significant disability. The recent development of custom printed biomaterial scaffolds that can fit and fill large bone defects may provide a novel solution and coating these scaffolds with agents designed to promote more rapid and complete bone healing may increase the efficacy of prosthetic scaffolds in healing segmental bone defects. Although currently used to promote bone generation, growth factors such as rh-BMP2 (BMP2) are of questionable efficacy and present significant safety issues. We have recently reported that adenosine A2A receptor (A2AR) stimulation increases osteoblast number and regulates osteoblast function in a murine model of inflammatory osteolysis and that A2AR stimulation diminishes osteoclast differentiation by inhibiting NFB activation and nuclear translocation. Moreover, A2ARs stimulate angiogenesis and vasculogenesis in vitro and in vivo. Thus, we propose to test the hypothesis that 3- dimensional printed scaffolds coated with an agent, dipyridamole, that increases local adenosine levels and indirectly stimulates A2ARs can further promote bone regeneration at critical sized segmental bone defects and to determine the cellular and molecular mechanisms for this phenomenon. We therefore propose the following aims: I. Development of coated bioactive ceramic scaffolds to treat critical segmental bone defects. We will determine whether implanting 3-dimensionally printed calcium triphosphate/hydroxyapatite scaffolds coated with dipyridamole, an agent which blocks cellular adenosine uptake and increases adenosine concentration in extracellular fluids, promotes bone regeneration in a rabbit radius model of segmental bone defect. We will further maximize scaffold design and dipyridamole dosing in vitro and in a murine calvaria model of bone regeneration. II. Determination of the cellular mechanism by which A2AR stimulation promotes bone regeneration. Using global and cell-selective knockouts of A2AR we will determine the cellular basis for A2AR-mediated bone regeneration in the murine calvaria model. III. Examination of the molecular mechanisms by which A2AR stimulation promotes bone regeneration in osteoblasts. We will test the hypothesis that A2AR signaling interacts with critical intracellular signaling cascades to promote bone regeneration using pharmacologic inhibitors of signaling pathways and by targeted knockdown of critical signaling molecules in primary cells and cell lines. The goals of this highly translational project are to establish the molecular and cellular basis for targeting A2ARs to stimulate bone regeneration and to rapidly translate these findings to the clinic.

Public Health Relevance

Defects in long bones may develop following trauma, infection or as a result of tumor invasion and and there is a clear need for better ways to promote bone regeneration. We have developed a novel approach to stimulating bone regeneration using a combination of 3D-printed, resorbable scaffolds coated with an agent that indirectly stimulates adenosine A2A receptors, dipyridamole. We propose here to maximize this approach to promoting bone regeneration and to rapidly bring these scaffolds to patients and to better understand the mechanism by which dipyridamole improves bone regeneration.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
3R01AR068593-03S1
Application #
9482916
Study Section
Program Officer
Wang, Fei
Project Start
2017-09-01
Project End
2019-04-30
Budget Start
2017-09-01
Budget End
2018-04-30
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10010
Friedman, Benjamin; Cronstein, Bruce (2018) Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine :
Mediero, Aránzazu; Wilder, Tuere; Shah, Lopa et al. (2018) Adenosine A2A receptor (A2AR) stimulation modulates expression of semaphorins 4D and 3A, regulators of bone homeostasis. FASEB J 32:3487-3501
Haskó, György; Antonioli, Luca; Cronstein, Bruce N (2018) Adenosine metabolism, immunity and joint health. Biochem Pharmacol 151:307-313
Yang, Lu; Fanok, Melania H; Mediero-Munoz, Aranzazu et al. (2018) Augmented Th17 Differentiation Leads to Cutaneous and Synovio-Entheseal Inflammation in a Novel Model of Psoriatic Arthritis. Arthritis Rheumatol 70:855-867
Lopez, Christopher D; Witek, Lukasz; Torroni, Andrea et al. (2018) The role of 3D printing in treating craniomaxillofacial congenital anomalies. Birth Defects Res 110:1055-1064
Bekisz, Jonathan M; Flores, Roberto L; Witek, Lukasz et al. (2018) Dipyridamole enhances osteogenesis of three-dimensionally printed bioactive ceramic scaffolds in calvarial defects. J Craniomaxillofac Surg 46:237-244
Lopez, Christopher D; Diaz-Siso, J Rodrigo; Witek, Lukasz et al. (2018) Three dimensionally printed bioactive ceramic scaffold osseoconduction across critical-sized mandibular defects. J Surg Res 223:115-122
Bonfante, Estevam A; Suzuki, Marcelo; Hirata, Ronaldo et al. (2017) Resin composite repair for implant-supported crowns. J Biomed Mater Res B Appl Biomater 105:1481-1489
Ishack, Stephanie; Mediero, Aranzazu; Wilder, Tuere et al. (2017) Bone regeneration in critical bone defects using three-dimensionally printed ?-tricalcium phosphate/hydroxyapatite scaffolds is enhanced by coating scaffolds with either dipyridamole or BMP-2. J Biomed Mater Res B Appl Biomater 105:366-375
Krasnokutsky, Svetlana; Oshinsky, Charles; Attur, Mukundan et al. (2017) Serum Urate Levels Predict Joint Space Narrowing in Non-Gout Patients With Medial Knee Osteoarthritis. Arthritis Rheumatol 69:1213-1220

Showing the most recent 10 out of 27 publications